Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

v3.20.1
Stockholders' Equity (Tables)
3 Months Ended
Mar. 31, 2020
Stockholders' Equity  
Summary of restricted stock award activity

The following table summarizes restricted stock award activity for the three months ended March 31, 2020:

 

 

 

 

 

 

 

 

 

 

Weighted Average 

 

 

Number of

 

Grant Date Fair

 

    

Shares

    

Value  

Nonvested at December 31, 2019

 

3,303,839

 

$

4.29

Granted

 

931,000

 

 

2.43

Vested

 

(235,314)

 

 

3.08

Nonvested at March 31, 2020

 

3,999,525

 

$

3.93

 

Summary of stock option award activity

The following table summarizes stock option award activity for the three months ended March 31, 2020:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average 

 

 

 

 

 

 

 

Remaining

 

 

 

 

Weighted Average 

 

 Contractual Life

 

    

Stock Options 

    

Exercise Price

    

(in years)

Outstanding as of December 31, 2019

 

160,000

 

$

3.64

 

8.56

Granted

 

40,000

 

 

1.94

 

 

Outstanding as of March 31, 2020

 

200,000

 

$

3.30

 

8.63

 

 

Summary of warrant activities

A summary of warrant activities for the three months ended March 31, 2020 is presented below:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average 

 

 

 

 

 

 

 

Remaining

 

 

 

 

Weighted Average 

 

Contractual Life

 

    

Warrants 

    

Exercise Price 

    

(in years)

Outstanding as of December 31, 2019

 

4,207,447

 

$

6.81

 

1.25

Exercised

 

(102,742)

 

 

0.13

 

 

Outstanding as of March 31, 2020

 

4,104,705

 

$

6.98

 

0.65

 

 

Summary of stock-based compensation expense

The following table summarizes stock-based compensation expense for the three  months ended March 31, 2020 and 2019 ($ in thousands):

 

 

 

 

 

 

 

 

 

For the three months ended March 31, 

 

    

2020

    

2019

Research and development

 

$

144

 

$

196

General and administrative

 

 

495

 

 

602

Total stock-based compensation expense

 

$

639

 

$

798